Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
Resistance training and walking can be beneficial for patients with multiple myeloma.
Certain Antidepressants Are Associated With Worse PFS in Pancreatic Cancer
Lorazepam was associated with worse survival outcomes for patients with pancreatic cancer, while alprazolam was associated with improved outcomes.
After Recruiting Oncology Nurses, Focus on Retention
Encourage professional development, foster resiliency, and engage nurse leaders to create an environment that not only brings in new nurses, but keeps them.
Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse
Children with high-risk Hodgkin lymphoma were 10% less likely to relapse following treatment with brentuximab vedotin combination
Pembrolizumab Plus Bevacizumab and Cyclophosphamide Shows Promising Efficacy, Tolerability in Recurrent Ovarian Cancer
Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Tackling the Adverse Events of Immunotherapy
Most patients who receive immunotherapies will experience few, if any, treatment-related adverse effects (AEs). But some patients receiving these treatments can experience serious AEs caused by an overactivation of the immune system and its effects on healthy cells.
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain Management
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Nurse Takeaways: How to Improve a Patient’s Experience With Sotorasib and Optimize NSCLC Treatment
Oncology nurses present their experiences treating patients with sotorasib in the phase 1/2 CodeBreaK 100 trial and optimal symptom management strategies to improve patient outcomes with the drug.
Will Requiring the DNP Improve the Quality of Oncology Nursing?
Advocacy and opposition continue to grow regarding the National Organization of Nurse Practitioner Faculties’ goal of requiring the Doctor of Nursing Practice degree (DNP) for entry-level nurse practitioners.
2-Year Follow-Up Showcases Sotorasib Benefit in KRAS G12C+ NSCLC
Longer follow-up data from the phase 1/2 CodeBreaK 100 trial show that patients with KRAS G12C–mutant non–small cell lung cancer experienced improved prolonged overall survival and encouraging response rates with sotorasib.
New Dosing Guide Will Maximize Buprenorphine Benefit Without Putting Patients at High Risk of Addiction
Experts from Roswell Park developed a dosing guide for the prescription of buprenorphine as treatment for chronic pain.
Roswell Park Nurse Residency Program Nationally Recognized and Accredited
With education one of the cornerstones of its mission, Roswell Park Comprehensive Cancer Center is pleased to announce that its Nurse Residency Program has achieved Accreditation with Distinction from the American Nurses Credentialing Center (ANCC).
Dr. Jamie Smith Joins Roswell Park as Chief Academic Officer
A longtime champion of education as “a great equalizer” will now lead Roswell Park Comprehensive Cancer Center’s broad slate of educational programs.
Roswell Park and University of Chicago Medicine Comprehensive Cancer Centers Awarded Nearly $9M for Ovarian Cancer Research
For years, scientists at Roswell Park Comprehensive Cancer Center and the University of Chicago Medicine Comprehensive Cancer Center have devoted themselves to research to better understand ovarian cancer.
Visceral Fat Index Score Questions Obesity-Survival Connection in Early-Stage Lung Cancer
Whether or not obesity should be considered a risk factor for non-small lung cancer might be determined by how it is measured.
Oral Contraceptives Decrease Risk of Ovarian Cancer Death
The use of oral contraceptives not only decreases a woman’s risk of developing ovarian cancer, but can also decrease the risk of dying from the disease, too, according to recent research.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512